Clinical Oncology

[Combining angiogenesis- and checkpoint-inhibitors to potentiate each other’s effects]

PIKÓ Béla1, BASSAM Ali1, MARIK László1

JUNE 30, 2021

Clinical Oncology - 2021;8(2)

[Both, the inhibition of angiogenesis and the influence of immune-mediated processes play significantly growing role in non-surgical treatment of tumors. Neoangiogenesis of neoplasmas adversely affects the function of the immune system, so its inhibition enhances the action of T-lymphocytes and other factors that support their function, favorably affects the microenvironment of the tumor, while treatment with immune signaling sites helps to normalize the vascular system. Influencing those two targeting points together may have a beneficial effect. Authors present that the combined use of agents having those two targets in renal cell carcinoma, melanoma malignum, non-small cell lung cancer, colorectal cancer, hepatocellular and breast cancer noting that successful phase III studies have been performed predominantly in clear cell (or tumor that also contains a clear cell component) carcinomas. The authors emphasize that immunotherapy usually requires the detection of susceptibility-predicting parameters (corresponding PD-L1, MSI-H, dMMR, TMB-H) and that registered indications should be considered in addition to the therapeutic philosophy of tumor agnostic treatment.]

AFFILIATIONS

  1. Békés Megyei Központi Kórház, Pándy Kálmán Tagkórház, Megyei Onkológiai Központ, Gyula

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[Relevance of adrenal insufficiency in the management of oncological patients]

IGAZ Péter

[Adrenal insufficiency has a complex relevance in oncology. On one hand, malignant tumors warranting treatment might develop in patients suffering from adrenal insufficiency, on the other hand, adrenal insufficiency might appear due to the progression of malignant tumor or to its therapy. During the progression of oncological disease, bilateral adrenal or very rarely pituitary metastases could result in adrenal insufficiency. Novel immune-checkpoint inhibitors, opioids and long-term glucocorticoid treatment can all lead to adrenal insufficiency. It is very important to recognize and to know the treatment of adrenal insufficiency, as failure of treating adrenal insufficiency might be related to severe, even fatal consequences. In this review, these clinically relevant fields are presented.]

Clinical Oncology

[The role of next-generation sequencing in clinival oncology]

KOTMAYER Lili, BÖDÖR Csaba

[Over the past decade next-generation sequencing has led to the in-depth understanding of the molecular background and driving mechanisms in most types of cancer. Parallel to the technological advances, novel targeted therapies have become available for oncology patients. As a result of this process, molecular diagnostics is now one of the main cornerstones of precision medicine with predictive biomarkers aiding patient care in oncology. In addition to standard monogenic testings, recently multigene testing methods based on next-generation sequencing came into view, supporting targeted therapeutic decisions and personalized medicine. In this review, we aim to depict the most important professional aspects related to the reasonable application of next-generation sequencing and the interpretation of its results.]

Clinical Oncology

[Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine]

CASOLINO R, BRACONI C, MALLEO G, PAIELLA S, BASSI G, MILELLA M, DREYER S B, FROELING FE M, CHANG D K, BIANKIN A V, GOLAN T

[Summary – This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of ‘all-comer’ treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.]

Clinical Oncology

[Microsatellites act as „seismographs” of the genome]

SÜKÖSD Farkas

[Short non-protein-coding repetitive regions consisting of 1-6 bp sequences are called microsatellites. Failure in DNA polymerase activity during replication may lead to an increase or reduction in the number of these repeats. Generally, these microsatellite number variations are corrected via the DNA repair machinery; if not, the alterations are transmitted to the progeny, which is also indicated by the elevated mutation rate in the offspring. Microsatellite instability (MSI) can also cause reading-frame problems, and this can lead to elevated expression of foreign antigens in tumors, promising an enhanced efficacy of the anti-tumour immune response. Thus, MSI indicates not only genetic instability but also an increased efficacy of immune checkpoint inhibitors. Various tools such as PCR-based techniques or immunohistochemical methods have been developed to confirm MSI and to examine the functionality of the DNA repair mechanisms in these patients. Additionally, the recent technology also allows us to examine of microsatellites by using next-generation sequencing or artificial intelligence-based image analysis methods. In this review, we summarize recent methodologies and the clinical significance of MSI analysis. ]

Clinical Oncology

[EMDR therapy in the treatment of oncology patients]

HAVELKA Judit

[The diagnosis and treatment of a life-threatening disease such as cancer involves exposure to psychological and physical stress and may constitute a traumatic experience for most people. Abnormal adaptation of neurobiological systems to the stress following experienced trauma, furthermore, individual fac­tors such as previous traumas may also play a role in PTSD development. In the context of oncology, there is a specific need to develop better tools for psychological assessment, that address cancer-related stressors. It is hypothesized that eye movement desensitization and reprocessing (EMDR) therapy promotes the elicitation of the innate self-healing capacity, the natural healing process of the immune system and adaptive information reprocessing. The EMDR therapeutic intervention with oncological patients aims to repair the psychic balance, empower resilience factors and to allow the processing of traumatic disease-related experiences.]

All articles in the issue

Related contents

Clinical Oncology

[Tyrosine-kinase inhibitors and bisphosphonates in the treatment of metastases from renal cell carcinoma]

EDUARD Vrdoljak, TOMISLAV Omrčen

[Bone metastases (BMs) are common in patients with renal cell carcinoma (RCC) and approximately in 30% of patients with metastatic RCC (mRCC) will develop. Inhibition of vascular endothelial growth factor (VEGF) has been pursued as a therapeutic target in the treatment of metastatic clear cell RCC (mRCC). Tyrosine kinase inhibitors (TKIs), such as sunitinib, pazopanib, sorafenib, and axitinib, became the therapy of choice for patients with mRCC. Apart from the undisputed effi cacy of TKI in treatment of mRCC, the problem of metastatic bone disease still remains. There is evidence that the presence of BMs in m-RCC patients has a signifi cant and clinically-relevant negative impact on survival and potentially on the outcome of VEGF-targeted therapy. Also, common practice in the treatment of such patients is bonedirected therapy with BPs. Recent evidence shows a potentially synergistic effect on effi cacy but also a potential impact on increased toxicity of combining TKIs and BPs. This review highlights the importance of this subject and aims to facilitate further research and optimize the treatment of this important and common group of RCC patients.]

Lege Artis Medicinae

[Dangers of the use of performance enhancement drugs and food supplements]

PUCSOK József

[The history of humankind is full of stories related to performance enhancement drug abuse. For the purpose of improving explosive power and long-term physical performance central nervous system stimulating drugs and supplements, such as: amphetamine and cocaine have been used. Androgenic anabolic steroids are used for increasing skeletal muscle mass. The abuse of performance enhancer drugs is seriously deteriorating the human health, and have several negative side effects. Number of food-supplements - available in the market, often contain traces of steroids. So called designer steroids are extremely dangerous. In the near future it will be possible to enhance physical performance through genetic interventions.]

Lege Artis Medicinae

[The calcium channel blocker verapamil basic properties, pharmacokinetics, interactions, side effects]

KÉKES Ede, FARSANG Csaba

[The family of calcium channel blockers is very large and includes its prototype, the monophenylalkylamin drug, verapamil. It is a non-selective vasodilator which exerts a powerful effect equally on myocardium, conducting and nodal tissue of the heart, and both central and peripheral vasculature. Verapamil is almost completely absorbed after oral administration. However, because of extensive first-pass hepatic metabolism, only about 20% of the drug is bioavailable. The elimination phase is slow with a half-time varying from 5 to 7 hours. Orally administered verapamil is extremely well tolerated drug with a very low incidence of gastric intolerance, constipation, vertigo, facial flushing headache and pruritus. During intravenous administration the most common side effects are hypotension and and occasional AV conduction disturbances, or bradycardia. Main contraindications are listed. Coadministration of beta receptor blokers, digitalis and disopyramid should be avoided. ]

Lege Artis Medicinae

[PAIN RELIEF IN THE CLINICAL PRACTICE - THE USE OF MAJOR ANALGETICS]

HORVÁTH J. Attila

[The use of opioids to relieve strong, unbearable pain is a method that has been known for thousands of years and is still effective today. In contrast to the earlier view, opioids today are not only given to cancer patients. The application area of morphine derivatives is generally the relief of exceptionally strong pain regardless of the diagnosis, but opiates are undoubtedly most commonly used to treat cancer-related or strong acute pain. Strong pain reducers are used much more in developed countries for the treatment of non-cancer related severe pain refractory to other approaches. Today the use of opiates and their derivatives (fentanyl, oxycodon) for non-cancer related pain relief is recognized by the national health insurance in that it allows general practitioners to prescribe them, upon the recommendation of a neurosurgeon, orthopaedic surgeon, traumatologist or rheumatologist, with a significant 90% subsidy for six months to ensure easy access for patients in severe, refractory pain due to degenerative musculoskelatal diseases (ICD: M47, M48, M16.9, M17.9, M54.4, M51.0, M51.1). The indications of opioid use, however, are not limited to strong nociceptive pain since they are also effective in certain types of peripheral neuropathic pain. In brief, a basic principle of the use of major analgetics is that their indication is primarily based on the intensity of pain and not on the nature of the disease, even though the latter has a major influence on the clinician's strategy of pain relief.]

Clinical Neuroscience

[Theoretical and practical considerations of rational polytherapy in epilepsy]

RAJNA Péter

[Author analyses the consideration of rational polytherapy for epilepsy. Among the theoretical aspects he points the different effect of seizure inhibitory drugs on the epilepsy models but didn’t find data enough for the basis of any successful combination. Combinations of compounds having different way of action are more promising. Rational polytherapy can serve also the epileptic patients’ tailored therapy in the daily routine. There have already been some proved synergisms concerning drug interactions. Based on detailed analysis of side effects a possibility occurs for neutralization of side effects when anticonvulsants with side effects of opposite nature are combined. Considering both the side effect profiles and the different (somatic and psychic) habits of the patients we can create a special list of favourable combinations. Co-morbid states and their treatments play a significant role in the application of rational polytherapy. Combination of anticonvulsants of lower potential but without drug-interactions can be the choice in these cases. The non-epileptic indications of the anticonvulsants can also be utilized in polymorbid patients. Based on the theoretical and practical considerations the author defines the ten-step-cognitive-preparation-process in planning the optimal (poly)therapy. On speculative basis he suggests eight beneficial versions of seizure inhibitory rational polytherapy.]